Long-term use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer
- 31 August 2007
- journal article
- Published by Elsevier BV in American Journal of Obstetrics and Gynecology
- Vol. 197 (2), 139.e1-139.e7
- https://doi.org/10.1016/j.ajog.2007.01.019
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Case-Control Study of Postmenopausal Hormone Replacement Therapy and Endometrial CancerAmerican Journal of Epidemiology, 2006
- Endometrial cancer and hormone-replacement therapy in the Million Women StudyThe Lancet, 2005
- National Use of Postmenopausal Hormone TherapyJAMA, 2004
- Effects of Estrogen Plus Progestin on Risk of Fracture and Bone Mineral DensityThe Women's Health Initiative Randomized TrialJAMA, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Risk of Endometrial Cancer Following Estrogen Replacement With and Without ProgestinsJNCI Journal of the National Cancer Institute, 1999
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJAMA, 1998
- Estrogen-Progestin Replacement Therapy and Endometrial CancerJNCI Journal of the National Cancer Institute, 1997
- Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal womenThe Lancet, 1997
- Effects of "natural oestrogen" replacement therapy on menopausal symptoms and blood clotting.BMJ, 1975